high-density lipoprotein ( HDL ) cholesterol increased ( 44 10 to 53 12 mg/dl , p < 0.005 ) and triglycerides decreased ( from 265 118 mg/dl to 149 37 mg/dl , p < 0.001 ) in the ezetimibe + fenofibrate group , whereas both parameters remained unchanged in the pravastatin group .